

(c) amino acids 1 to 547 of SEQ ID NO: 15.

Cont
E1

39. (Amended) A monoclonal antibody or fragment thereof of claim 38, wherein the antibody or fragment thereof binds a polypeptide consisting of amino acids 1 to 524 of SEQ ID NO: 11.

E2

42. (Amended) A monoclonal antibody or fragment thereof that binds a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 11.

43. (Amended) A pharmaceutical composition comprising an antibody of claim 42 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer, or diluent.

E3

46. (Amended) A pharmaceutical composition comprising an antibody of claim 38 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer, or diluent.

Please add the following new claims 47-56:

E4
5/1/02

47. (New) An antibody or fragment thereof which is raised against at least a portion of a polypeptide comprising SEQ ID NO: 11.

48. (New) The antibody of claim 47 which is a monoclonal antibody.

Cont
E4

49. (New) The antibody of claim 47 which is a chimeric antibody.
50. (New) The antibody of claim 47 which is a CDR-grafted antibody.
51. (New) A pharmaceutical composition comprising an antibody of claim 47 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer, or diluent.
52. (New) An antibody or fragment thereof which is raised against at least a portion of amino acids 1 to 524 of SEQ ID NO: 11.
53. (New) The antibody of claim 52 which is a monoclonal antibody.
54. (New) The antibody of claim 52 which is a chimeric antibody.
55. (New) The antibody of claim 52 which is a CDR-grafted antibody.
56. (New) A pharmaceutical composition comprising an antibody of claim 52 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer, or diluent.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com